Details of the Drug Combinations

General Information of This Drug (ID: DMPI98T)

• Drug Name: Doxepin (DMPI98T)
• Synonyms: Zonalon; doxepin; Doxepine; Doxepinum [INN-Latin]; Doxepina [INN-Spanish]; Doxepin [USAN]; trans-doxepin; (e)-doxepin; 1668-19-5; Quitaxon; MF 10; UNII-851NLB57HQ; Sinequan; CCRIS 9176; HSDB 3069; Sinequan (TN); Cidoxepina; Cidoxepinum; 851NLB57HQ; 11-(3-(Dimethylamino)propylidene)-6H-dibenz(b,e)oxepine; 11-(3-Dimethylaminopropylidene)-6,11-dihydrodibenz(b,e)oxipin; 11-(3-Dimethylamino-propyliden)-6,11-dihydro-dibenz(b,e)oxipin; N,N-Dimethyldibenz(b,e)oxepin-delta(11(6H),gamma)-propylamine; Cidoxepin [INN]; Curatin; Adapin; Cidoxepin; Doxepina; Doxepinum; Triadapin; Doxepin Hydrochloride; MOLI001594; Adapine (TN); Aponal (TN); Cis-doxepin; Deptran (TN); Doxepin (INN); Doxepin, Hydrochloride; Sinquan (TN); Xepin (TN); Zonalon (TN); Doxepin (Z)-isomer; Cis-N-(3-(6H-Dibenz(b,e)oxepin-11-yliden)propyl)-N,N-dimethylamin; (3E)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine; (3E)-3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine; (3Z)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-di(methyl)propan-1-amine; (3Z)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine; (3Z)-3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine; (Z)-Doxepin; 3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine; 3-Dibenz[b,e]oxepin-11(6H)-ylidene-N,N-dimethyl-1-propanamine; 3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine; [11C]doxepin

Indication

Anxiety; ICD 11: N.A.; Status: Approved [1]; Bipolar depression; ICD 11: N.A.; Status: Approved [1]; Depression; ICD 11: 6A70-6A7Z; Status: Approved [2]; Insomnia; ICD 11: 7A00-7A0Z; Status: Approved [1]; Pruritus; ICD 11: EC90; Status: Investigative [1]

• Therapeutic Class: Antidepressants
• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

13 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Doxepin + Lumefantrine	DCFIL85	Lumefantrine	DD2 (Cell Line: DD2)	[3]
Doxepin + Artemether	DC3UFMS	Artemether	DD2 (Cell Line: DD2)	[3]
Doxepin + Diltiazem	DCRMSHN	Diltiazem	DD2 (Cell Line: DD2)	[3]
Doxepin + Sarpogrelate	DCWX6XW	Sarpogrelate	DD2 (Cell Line: DD2)	[3]
Doxepin + Miconazole	DC0F50P	Miconazole	DD2 (Cell Line: DD2)	[3]
Doxepin + Quinine	DC3ZGTP	Quinine	DD2 (Cell Line: DD2)	[3]
Doxepin + Mefloquine	DCR9A55	Mefloquine	DD2 (Cell Line: DD2)	[3]
Doxepin + Atovaquone	DCA1W65	Atovaquone	DD2 (Cell Line: DD2)	[3]
Doxepin + Pyrimethamine	DC8C7WP	Pyrimethamine	Hepatoblastoma (Cell Line: HB3)	[4]
Doxepin + Docetaxel	DCN7JVC	Docetaxel	Hepatoblastoma (Cell Line: HB3)	[4]
Doxepin + MK-4815	DCI9NSZ	MK-4815	Hepatoblastoma (Cell Line: HB3)	[4]
JTC-801 + Doxepin	DCWT268	JTC-801	DD2 (Cell Line: DD2)	[3]
Omacetaxine mepesuccinate + Doxepin	DCZ7IDU	Omacetaxine mepesuccinate	DD2 (Cell Line: DD2)	[3]

References

• [1] Doxepin FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1225).
• [3] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [4] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.